StockWatch: FDA Panel Enables Accelerated OK for Biogen ALS Drug
Mixed votes from an FDA advisory panel may help Biogen secure accelerated approval of ALS drug tofersen, licensed from Ionis Pharmaceuticals.
Stay updated with breaking news from Accelerated Approval Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mixed votes from an FDA advisory panel may help Biogen secure accelerated approval of ALS drug tofersen, licensed from Ionis Pharmaceuticals.
A federal judge pressed both sides in a hearing on Wednesday questioning FDA approval of an abortion drug.
On February 14, 2023, the U.S. Department of Health and Human Services (HHS) published a report identifying three models that the Center for Medicare & Medicaid Services’ (CMS) Center...
If proposed and finalized as described, this profound policy shift would inevitably chill incentives for leveraging the FDA’s game-changing expedited regulatory avenue, which has served patients with life-threatening diseases for decades. Later approvals and access delays would follow.
Andrew N. Wilner, MD, and Richard J. Caselli, MD, discuss developments in the treatment of Alzheimer's disease.